Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Primary ciliary dyskinesia

Orpha number ORPHA244
Synonym(s) PCD
Prevalence -
Inheritance Autosomal dominant
Autosomal recessive
X-linked dominant
Age of onset Neonatal
ICD-10
  • J98.0
ICD-O -
OMIM
UMLS -
MeSH -
MedDRA
  • 10069713

Summary

Primary ciliary dyskinesia (PCD) is a rare, genetically heterogeneous, primarily respiratory disorder characterized by chronic upper and lower respiratory tract disease. Approximately half of PCD patients have an organ laterality defect (situs inversus totalis or situs ambiguus/heterotaxy; see these terms).

PCD has an estimated incidence of 1/15,000-1/30,000 live births, but this is probably an underestimate. Prevalence is difficult to determine.

Affected patients develop signs of PCD at birth or within the first few months of life. Most full-term neonates have respiratory distress with tachypnea (infant acute respiratory distress syndrome) and usually require supplemental oxygen for days, some for weeks. The usual findings in infants and children are daily rhinitis, and daily year-round wet cough occurring soon after birth, with associated recurrent or chronic bacterial infections of the lower airways. Chronic otitis media is common, sometimes with temporary or permanent hearing loss and impaired speech development. Most patients have recurrent sinus infections. Bronchiectasis develops in an age-dependent manner, and is nearly universal in adults. Pectus excavatum and scoliosis have been reported rarely (5-10%), as well as digital clubbing. Almost all males with PCD are infertile, due to dysmotility of spermatozoa, although a few have normal sperm motility. Reduced fertility or a history of ectopic pregnancies has been reported in affected women. Situs inversus totalis, a mirror-image reversal of all visceral organs, is found in 40-50% of individuals and is known as the Kartagener type. Heterotaxy (discordance of right and left patterns of normally asymmetric structures) is present in at least 12%, and a subset of those have structural congenital heart disease. A very rare association of X-linked PCD with either retinitis pigmentosa or intellectual deficiency (see these terms) has been reported.

Pulmonary disease in PCD is related to defects in lung defense mechanisms due to abnormal ciliary structure and function with impaired mucociliary clearance. Mutations in around 30 different genes throughout the genome have been found to be causative. These include DNAH5 15%-21% of cases, CCDC39 2-10%, DNAI1 2%-9%, CCDC40 1-8%, DNAH11 6%, DNAAF1 4-5%, LRRC6 3%, DNAI2 2%, and DNAAF2 <2%. A third of currently recognized patients do not have mutations in these genes.

Diagnosis is based on the characteristic clinical signs and methods include transmission electron microscopy (TEM) identifying specific ciliary ultrastructural defects in biopsy samples and high-speed videomicroscopy to assess cilia waveform and beat frequency. Molecular genetic testing of the causative genes can confirm diagnosis.

The main differential diagnoses are cystic fibrosis (see this term), immunodeficiency syndromes, gastroesophageal reflux, and Wegener's Granulomatosis (see this term).

If disease-causing mutations are known in a family, prenatal diagnosis can be performed.

PCD is inherited in an autosomal recessive manner. Genetic counseling should be provided to affected families. Rare reports mention X-linked or autosomal dominant inheritance.

Regular clinical visits to monitor disease status are key. Aggressive treatment to improve mucus clearance is recommended. Antibiotic therapy is required and routine immunization is recommended. Sinus disease can be treated with nasal steroids and nasal lavage. Polyps may require surgical treatment. Patients with end-stage lung disease are candidates for lung transplantation. Audiological assessment, hearing aids, and communication assistance should be offered where necessary.

The prognosis depends on timely diagnosis and appropriate treatment. Life expectancy is likely somewhat shortened, although quantitative estimates are not currently available.

Expert reviewer(s)

  • Dr Michael KNOWLES
  • Dr Maimoona ZARIWALA

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Review article
  • EN (2014)
Clinical practice guidelines
  • EN (2009)
Clinical genetics review
  • EN (2013)
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.